Kornimate/medical-research-clean huggingface dataset:
endocuff enhanced colonoscopy: does it improve polyp detection and make rectal retroflexion unnecessary

Conditions: Colorectal Cancer; Colonic Polyps

Summary: the investigators hope that this project will determine if the endocuff device is a useful adjunct during colonoscopy by optimizing polyp detection and eliminating the need for the painful rectal retroflexion. as such, by improving polyp detection and eliminating the need for rectal retroflexion, it will directly reduce the likelihood of colon cancer and improve patient comfort respectively.

every day, 73 canadians are diagnosed with colorectal cancer. this cancer is the third most diagnosed type of cancer in canada while being the second and third most deadly cancer for men and women respectively. in addition, it accounts for 12% of all cancer diagnoses and cancer deaths for both sexes in 2020. fortunately, colorectal cancer incidence and mortality rates have been steadily declining in the recent years. this can be attributed to the development of new screening methods and devices assisting in a more reliable identification of polyps as well as removal during colonoscopy. this is essential to prevent cancer as these usually asymptomatic and harmless clusters of atypical cells can turn into cancers, and become fatal if they can progress to a later stage of their development. the endocuff is a new colonoscopy assisting device designed to aid physicians to maneuver inside the colon, allowing for increased detection of polyps that stay hidden between folds in the colon. by its flexible and hinged arms, the endocuff is designed to gently flatten the large colonic folds during withdrawal of the colonoscope, bringing the difficult-to-see mucosa to view. the endocuff also may assist in the view of the rectum, being the last area of the colon and difficult to assess. usually, a painful procedure called a retroflexion is used to help see this area. however, this pain can limit the evaluation and impact polyp diagnosis in the rectum. in this study, the investigators aspire to answer these following questions: (1) can the endocuff improve polyp detection? (2) can the endocuff replace the need for retroflexion in the rectum?

Eligibility criteria:
inclusion criteria: * any patient undergoing a colonoscopy during the study period * procedure being performed by a gastroenterologist (i.e., surgeons are excluded) exclusion criteria: * inflammatory bowel disease * hereditary mixed polyposis syndrome * diverticulitis * colonic stricture * toxic megacolon * previous colon surgery, excluding appendectomy * radiation therapy to abdomen or pelvis * pregnancy/lactation * anticoagulant use * suffered stroke or ischemia in previous 3 months * being deemed too risky by investigator * fit positive * poor preparation

Keywords: endocuff retroflexion colonoscopy polyp detection screening
multidrug resistant gram-negative bacilli colonization and infection in burn

Conditions: Multi-drug Resistant Gram-negative Bacilli Colonization

Summary: this is a prospective observational study to determine the role of colonization and identify the timing of development of drug resistance in multidrug resistant gram-negative bacilli (mdr-gnb) causing infection among critically ill burn patients.

this is a prospective observational study. patients will be followed during a single admission for development of colonization or infection with mdr-gnb. patient clinical characteristics, including infections, surgeries, and antibiotic exposure, will be collected in real-time. weekly surveillance wound and peri-rectal swabs and, if intubated, biweekly deep endotracheal or tracheostomy aspirates will be collected, de-identified, and stored from all patients and examined for the presence of mdr-gnb. all gnb isolates from blood, urine, respiratory, and wound cultures will be collected, coded, and stored.

Eligibility criteria:
inclusion criteria: 1. severe burn injury, including partial or full thickness burn 20% or more total body surface area; or 2. inhalation injury; or 3. 18 years of age or older; exclusion criteria: 1. intensive care unit stay of less than 5 days; 2. icu admission more than 48 hours after burn trauma.

Keywords: multidrug resistance burns infections, gram-negative bacilli ventilator-associated pneumonia ventilator-associated tracheobronchitis gram-negative bacilli colonization
a comparison of paclitaxel-based three regimens concurrent with radiotherapy for patients with local advanced esophageal cancer

Conditions: Stage III Esophageal Squamous Cell Carcinoma

Summary: the purpose of this study is to determined the best scheme in paclitaxel and cisplatin，paclitaxel and fluorouracil，paclitaxel and carboplatin concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria to be eligible for this study, patient must fulfill all of the following criteria: 1. histologically confirmed esophageal squamous cell carcinoma 2. clinical stages ii, iii or iva based on the 6th uicc-tnm classification 3. no prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer, except for non-curative resection by emr/esd. 4. aged 18-75 years 5. adequate organ functions 1. white blood cell (wbc) ≥3×109⁄l 2. absolute neutrophil counts (anc) ≥1.5×109⁄l 3. hemoglobin (hb) ≥10g⁄dl 4. platelet (plt) ≥100×109⁄l 5. total bilirubin \<1.5 upper limit of normal (uln) 6. aspartate transaminase (ast) ≤2.5 uln 7. alanine aminotransferase (alt) ≤2.5 uln 8. creatinine ≤1.5 uln 6. ecog ps of 0-2 7. life expectancy ≥3 months 8. written informed consent exclusion criteria patients fulfilling any of the following criteria are ineligible for this study. 1. esophageal perforation or hematemesis 2. synchronous or metachronous malignancies (except for cutaneous (non-melanomas) carcinoma, thyroid papillary carcinoma, phase i seminoma or cervical carcinoma in situ curatively treated and disease free for a minimum of 3 months) 3. received thoracic, abdominal or craniocerebral surgery within 30 days 4. enrolled in other clinical trials within 30 days 5. unstable angina and/or congestive heart failure requiring hospitalization within 6 months 6. severe psychiatric disease 7. pregnancy, lactation or unwillingness to adopt contraception 8. drug addiction 9. acquired immune deficiency syndrome (aids) based upon current cdc definition 10. patients with hearing impairment or sensory-motor neuropathy of who grade \> 1 11. history of radiotherapy in the planning area 12. other ineligible conditions according to researchers

Keywords: esophageal squamous cell carcinoma concurrent chemoradiotherapy paclitaxel cisplatin carboplatin fluorouracil
development of predictive indicators of homogeneous propagation of ultrasound and elastic waves during vcte examination

Conditions: Liver Fibrosis

Summary: this is an european, prospective, interventional, and multicenter exploratory clinical investigation that will take place in 6 french sites and 200 patients will be included (adults and children). the study objective is to develop predictive indicators of homogeneous propagation of ultrasound and elastic waves to define an optimal region of interest for the measurement of liver stiffness during vcte examination.


Eligibility criteria:
inclusion criteria: * adult and pediatric patients, all etiologies combined * patient must be able to give written informed consent, or the parents in the case of a minor patient * patient affiliated to a social security system exclusion criteria: * vulnerable patient- other than pediatric patients * pregnant or breastfeeding woman

Keywords: fibroscan vibration control transient elastography vibration guided transient elastography liver stiffness measurement vcte vgte
efficacy of increasing physical activity to reduce children's visceral fat

Conditions: Obesity

Summary: the purpose of this trial is to examine whether adding greater physical activity to standard family-based behavioral pediatric obesity treatment decreases the amount of visceral fat among treated overweight children.

adult studies suggest that greater visceral fat confers more health risk than peripheral fat accumulation and that physical activity interventions (as part of general weight control interventions) are efficacious in reducing adults' visceral fat. there are few studies examining the impact of physical activity and/or general weight loss on children's visceral fat accumulation. the present study compares standard family-based behavioral weight control treatment for pediatric obesity (standard) with standard treatment plus added emphasis on participants attaining high levels of physical activity (added). both conditions receive the same behavioral dietary intervention and therapeutic contact and attention. the added condition receives the recommendation and goal to be active at least 90 minutes per day, with behavioral strategies targeting increasing and sustaining these high levels of physical activity.

Eligibility criteria:
inclusion criteria: * 7-12 years old * \>85th percentile bmi * have at least one parent with a bmi\>25 * able to engage in at least moderate intensity physical activity * child and parent willing and able to participate in behavioral treatment * english-speaking exclusion criteria: * child or parent already enrolled in another weight control program * child or parent with a medical condition known to affect weight or growth * child or parent with significant mental illness that would interfere with engaging in treatment * child or parent with a current or past diagnosed eating disorder * child or parent currently taking any medication that affects weight or growth * child who is more than 120% above their median bmi for age and gender

Keywords: pediatric obesity physical activity visceral fat weight
the role of pre-operative and post-operative circulating tumor cells in gastric cancer.

Conditions: Carcinoma

Summary: in resectable gastric cancer participants who received curative surgery, to early and more accurately detect peritoneal carcinomatosis or occult metastasis is important. also, investigators will look at ctc numbers in different timings after operation, to investigate the possibility of early detection for peritoneal carcinomatosis or occult metastasis. also, this study will correlate the relationship of ctc and participants' survival.

circulating tumor cells (ctcs) are an emerging "liquid biopsy" that provide prognostic value for various types of solid cancer on early recurrence and survival. the evaluation of ctcs might be a useful strategy to predict tumor progression and prognosis in gastric adenocarcinoma (gc). previous study has shown that the frequency of ctc detection was higher in advanced gc than early gc, in poorly differentiated gc than well/moderately differentiated gc, and in gc with lymphatic metastasis than that without lymphatic metastasis. however, the impact of ctcs in the detection of pm in gc is still under debate. peritoneal metastasis (pm) is highly related to recurrence and metastasis in gc; therefore, it was significantly related to disease free and overall survival of participants. consequently, several important questions and goals will be answered by this study: to elucidate the clinical relationship between ctcs and pm in gcs before the operation; therefore, it could be an indicator of prophylactic during operation, which may possibly prolong the disease free and overall survival. to establish a good model to follow-up a specific surface marker on ctcs, which could be possibly utilized as a more sensitive marker, comparing with cea or image study, to more accurately detect the early recurrence or metastasis in gc. to verify that dynamically monitoring ctcs status and changes during long-term follow-up and anti-cancer treatment are feasible and clinically meaningful to survival or treatment responses.

Eligibility criteria:
inclusion criteria: * enrolling 150 cases * stage i or more advanced gastric cancer, pathology proved * diagnosed at age ≥ 20 years * enrolled before surgery at the general surgery department, both inpatient and outpatient services. exclusion criteria: * patient's refusal * poor compliance, unable to cooperate for blood sampling for ctc isolation as time schedule or clinical treatment or follow-up * difficult blood sampling * no more needs for ctcs evaluation, decided by clinicians.

Keywords: circulating tumor cells gastric cancer peritoneal carcinomatosis recurrence metastasis
nasya in allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to evaluate safety and efficacy of nasya in reducing symptoms of persistent allergic rhinitis when applied before allergen challenge.


Eligibility criteria:
inclusion criteria: * history of persistent allergic rhinitis due to house dust mite allergy ≥ 2 years * written informed consent exclusion criteria: * clinically significant disease that could interfere with the evaluation of study medication * participation in other studies within the last 4 weeks / during the study

Keywords: allergic rhinitis allergen allergy dustmite
a study of galcanezumab (ly2951742) in adults with treatment-resistant migraine

Conditions: Migraine

Summary: the purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.


Eligibility criteria:
inclusion criteria: * have a diagnosis of migraine or chronic migraine. * history of migraine headaches at least 1 year prior to screening, with onset prior to age 50. * history of at least 4 migraine headache days and at, with at least 1 headache-free day per month on average within the past 3 months. * have documentation of 2 to 4 migraine preventive medication category failures due to inadequate efficacy or tolerability, in the past 10 years. exclusion criteria: * are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product. * current use or prior exposure to galcanezumab or another calcitonin gene-related peptide (cgrp) antibody. * history of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine). * pregnant or nursing.

Keywords: prevention prophylaxis headache treatment-resistant treatment resistant
genetics of insulin and incretins in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: cystic fibrosis related diabetes (cfrd) is associated with worse cf-relevant outcomes. the mechanisms underlying cfrd development are not fully understood, but recent evidence suggests type 2 diabetes mellitus (t2dm) mechanisms may be involved and may involve incretins (gut secreted hormones that augment insulin secretion in response to a nutrient load). this study will examine the prevalence of genome wide association study (gwas)-implicated t2dm alleles (including tcf7l2) across the spectrum of glucose abnormalities in cf and will use this information to compare incretin and insulin secretion in non-diabetic children and adults with high risk and low risk alleles.

cfrd is associated with worse nutritional status, greater pulmonary function decline, and increased mortality, highlighting its relevance in cf and arises primarily from compromised insulin secretion--traditionally considered a by-product of pancreatic exocrine tissue damage and fibrosis. recent developments in the field of diabetes are propelling a re-examination of this basic explanation. genome-wide association studies have associated genetic variants in tcf7l2, a transcription factor implicated in enteroendocrine function, with increased susceptibility to t2dm and cfrd. the objectives of this study are to perform targeted sequencing of tcf7l2 and other gwas-associated t2dm genes in the pediatric and adult cf populations and then to compare insulin secretory capacity, β-cell sensitivity to glucose, and incretin secretion in non-diabetic cf subjects with high and low-risk alleles. phase 1 will include 450-500 subjects (children age\>= 2 years, adolescents, and adults) for tcf7l2 genotype and ten other gwas-implicated t2dm genes. the distribution of tcf7l2 and other gwas-implicated t2 dm genes across the spectrum of glucose abnormalities will be described. phase 1 requires a single blood or saliva sample and review of medical records.

Eligibility criteria:
inclusion criteria 1. subjects age \>2y 2. diagnosis of cystic fibrosis 3. for subjects\< 18 years, parental/guardian permission (informed consent) and if appropriate, child assent exclusion criteria 1. established diagnosis of non-cfrd (cystic fibrosis related diabetes) (e.g t1dm) .
adjuvant treatment of prostate cancer with docetaxel or not after radical radiotherapy

Conditions: Prostate Cancer

Summary: as docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after radiotherapy to prevent early relapse. this will therefore be tested in a randomised phase iii trial where patients will be randomized either to docetaxel or surveillance

primary endpoint: * psa progression rate, astro guidelines. secondary endpoints: * psa doubling time after progression * quality of life (qol) * safety * metastases free survival * overall survival

Eligibility criteria:
inclusion criteria: * men \> 18 and ≤75 years of age. * who/ecog performance status 0 - 1. * histological proven adenocarcinoma of the prostate within 12 months prior to randomisation * one of the following: * t2 with gleason score 7(4+3 ) and psa \>10 ng/ml to \< 70 ng/ml * t2 with gleason 8-10, any psa \< 70 ng/ml * any t3 tumour * prior neoadjuvant hormone therapy is mandatory for all patients * adequate haematological-, liver- and kidney function. (hemoglobin \> 110 g/l, neutrophils \> 1.5 x 109/ l, platelets \> 150 x 109/ l, asat and alat \< 1.5 x uln, alp \< 1.5 x uln, creatinine \< 1.5 x uln) * written informed consent exclusion criteria: * m+ * n+ clinical or pathological * patients with a history of previous malignant disease. exceptions should be made for basal cell carcinoma (bcc) and squamous cell carcinoma of the skin. exceptions should also be made for curatively treated malignant disease, which has been disease free for the past five years. * previous radiotherapy to the pelvic region. * previous chemotherapy within 5 years. * systemic corticosteroids within 6 months prior to randomisation. * unstable cardiovascular disease, including myocardial infarction, within 6 months prior to randomisation. * active untreated infectious disease, including tuberculosis, mrsa. * active gastric ulcer. * known hypersensitivity to polysorbate 80 (an excipient of docetaxel) * other serious illness or medical condition

Keywords: adjuvant treatment, high risk, radical radiotherapy
i use lr in the ed

Conditions: Kidney Injury

Summary: to study the difference in mortality and major adverse kidney events during and after treatment in the emergency department with intravenous fluids per standard of care at 30 days before and after the system-wide implementation.


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years) receiving a minimum of 1000ml of intravenous fluids starting in the emergency department per standard of care exclusion criteria: * patients aged ≤17 years * previously enrolled patients with \>1 ed admission within the 30-day follow-up period
cor loco-regional advanced lung cancer treated with chemo-radiotherapy (cola)

Conditions: Cardiac Toxicity; Lung Cancer Stage III; Lung Cancer Stage II; Radiation Toxicity; Cardiac Disease

Summary: patients with loco-regional nsclc planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ecg and cardiac mr for at least two years after radiotherapy treatment.

definitive chemo-radiotherapy is the treatment of choice for loco-regional advanced non-small cell lung cancer (la-nsclc). however, the treatment is associated with a range of side effects with radiation pneumonitis and esophagitis. in addition, the toxicity of the heart in lung cancer patients treated with radiotherapy has been offered less consideration. therefore, it is essential to investigate the possible early and late toxicity to the heart and the baseline cardiac status of these patients. this study will describe cardiac comorbidity before radiotherapy treatment by a thorough history. furthermore, we will evaluate heart function and evaluate possible heart disease by an ecg and cardiac mr. patients will be followed with ecg and cardiac mr for two years after radiotherapy, detecting structural changes caused by radiotherapy and subclinical disease after radiotherapy.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * inoperable and histologically/cytologically verified nsclc. * planned treatment with curative intent. * capable of completing study procedures ecg and cardiac mr. * able of giving written and informed consent before study procedures are initiated. exclusion criteria: * vulnerable patients. * patients with operable devices as pacemaker/icd and cochlear implant or other conditions where mr scan is contraindicated. * claustrophobia.
a study of xolair in peanut-allergic subjects previously enrolled in study q2788g

Conditions: Peanut Hypersensitivity

Summary: this is a phase iib, multicenter, open-label study available to active (xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for study q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.


Eligibility criteria:
inclusion criteria: * completion of last visit (or early termination visit, if applicable) for study q2788g * signed informed consent form * use of an effective method of contraception for females of childbearing potential * body weight ≥ 20 kg and ≤ 150 kg * ige level ≤ 1300 iu/ml (note: subjects with an ige \< 30 iu/ml will be dosed at the lowest level on the dosing table \[30 iu/ml\], thus enabling better understanding of the role of xolair in peanut allergic subjects who have low total ige levels.) exclusion criteria: * withdrawal from study q2788g prior to study closure or the final study visit (week 36) * current participation in another investigational study * pregnancy or lactation * history of brittle asthma * aspirin-sensitive asthma * known hypersensitivity to any ingredients of xolair, including its excipients (sucrose, histidine, polysorbate 20) * have a polymorrphonuclear count \<1500/ul * use of anti-coagulants, such as warfarin (coumadin(r)), thrombolytic enzymes, or ticlopidine * current diagnosis of cancer, current investigation for possible cancer, or history of cancer (not including non-melanoma skin cancer) * thrombocytopenia as evidenced by a platelet count \< 100,000/ul * any systemic condition requiring regular administration of an immunoglobulin

Keywords: tops peanut allergy peanut-induced allergy allergy